Encouraging results have emerged from two phase II clinical trials investigating a novel treatment, PER-001, for glaucoma and diabetic retinopathy, two of the most common causes of blindness globally. Delivered via a sustained-release intravitreal implant every six months, PER-001 improved both vision and retinal structure compared with control groups.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
Taking place from 7–9 June 2025 in Lisbon, Portugal, the SOE Congress is one of Europe's leading multi-specialty ophthalmology meetings. With a world-class scientific programme, this in-person event offers a rich mix of symposia, live surgery, debates, workshops, mystery cases and updates ...
Susvimo® (ranibizumab injection) has become the first FDA-approved continuous delivery system for diabetic retinopathy (DR), reducing treatment frequency to once every nine months.1 The approval is based on the positive results of the phase III Pavilion study, showing significant improvement in disease severity.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
This episode explores the inspiring work of Orbis International, a nonprofit preventing blindness and restoring sight in underserved communities. Dr Maria Berrocal, Associate Professor and Orbis Volunteer Faculty, shares her experience aboard the Orbis Flying Eye Hospital, a fully equipped surgical and teaching hospital on an aircraft, and discusses the importance of global collaboration in building sustainable, high-quality eye care systems around the world.
Since its inception in November 2022, ChatGPT-3.5 has gained increasing popularity.1,2 ChatGPT is an artificial intelligence (AI) language application that performs online tasks and mimics human conversations using a question-and-answer format.3Â The interface has found widespread use in several industries, with ...
In this interview, Dr SriniVas Sadda, Director of Artificial Intelligence & Imaging Research at the Doheny Eye Institute, and Professor of Ophthalmology at the University of California – Los Angeles (UCLA) Geffen School of Medicine, and President of ARVO (2024-2025), discusses the pressing challenges and emerging opportunities in treating retinal diseases. Despite progress, many conditions, such as inherited retinal disorders, macular degeneration and diabetic retinopathy, still lack effective treatments. Dr Sadda shares the latest advancements in diagnostic tools like imaging, which provide a deeper understanding of these diseases at the cellular level and emphasizes the need to expand access to eye care, particularly as the aging population and conditions like diabetes drive up demand. Dr Sadda also highlights ARVO’s role in uniting researchers, clinicians and engineers worldwide to foster collaboration and accelerate progress in addressing these critical issues in vision health.
The uvea is a vascular stratum that includes the iris, ciliary body and choroid. Uveitis is defined as inflammation of a part of the uvea or its entirety, but it is also used to describe inflammatory processes of any part ...
The EURETINA 2024 Congress, held in Barcelona from September 19-22, brought together leading experts in ophthalmology to share the latest research and innovative treatments for retinal diseases. Among the highlights were several late-breaking abstracts that showcased promising advances in therapeutics for conditions such as retinopathy of prematurity (ROP), diabetic retinopathy (DR) and age-related macular degeneration (AMD). These studies not only demonstrated the efficacy and safety of novel treatment options but also addressed critical unmet needs in reducing patient burden and improving long-term outcomes.
Dry eye disease (DED) is a prevalent ocular condition characterized by discomfort, visual disturbances and tear film instability due to insufficient tear production or rapid tear evaporation.1Â With an increasing global incidence (i.e. up to 50%) and its significant impact ...
Thyroid eye disease (TED) is an autoimmune condition that can lead to significant visual impairment, facial disfigurement and decreased quality of life. It affects 16 out of every 100,000 females and 2.9 out of every 100,000 males. Risk factors for TED include age, female ...
Contrast sensitivity (CS), which is an important element of functional vision, helps in differentiating an object from its background. CS affects several aspects of vision, such as acuity, dark adaptation, visual field, motion detection and pattern recognition.1 A decline in ...
Welcome to the latest edition of touchREVIEWS in Ophthalmology, and my first as the journal’s Editor-in-Chief. In this issue, we are delighted to present a series of compelling articles providing insights into some of the cutting-edge developments in this ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.